Anti-Fibrinolytic Drugs - Chile | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in Chile is expected to witness a significant increase in revenue, projected to reach US$38.79m in 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 4.62%, leading to a market volume of US$48.62m by 2029.
When compared globally, United States is set to generate the highest revenue in this market, with an estimated US$9.86bn in 2024.
Chile's anti-fibrinolytic drug market is witnessing a surge in demand due to the country's aging population and increasing prevalence of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Chile has been experiencing growth in recent years.

Customer preferences: Chile has an aging population, which has led to an increase in the incidence of diseases such as cardiovascular disease and cancer. These diseases often require surgery, which can lead to bleeding complications. Anti-fibrinolytic drugs are used to prevent excessive bleeding during surgery, making them an attractive option for patients and healthcare providers.

Trends in the market: The Anti-Fibrinolytic Drugs market in Chile has been growing due to the increasing demand for these drugs in surgical procedures. The market is expected to continue to grow as the population ages and the incidence of cardiovascular disease and cancer continues to rise. In addition, the market is expected to be driven by the development of new drugs and formulations that are more effective and have fewer side effects.

Local special circumstances: Chile has a well-developed healthcare system that provides universal coverage to its citizens. This has led to increased access to healthcare services, including surgical procedures. In addition, the country has a strong pharmaceutical industry, which has helped to drive the development and availability of anti-fibrinolytic drugs.

Underlying macroeconomic factors: Chile has a stable economy with a strong mining sector, which has helped to drive economic growth in recent years. This has led to increased investment in healthcare infrastructure and technology, which has helped to improve access to healthcare services and surgical procedures. In addition, the country has a well-educated workforce and a favorable business environment, which has helped to attract foreign investment and drive innovation in the pharmaceutical industry.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.